Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent seasonal influenza vaccine-Emory University-Yellow Fever-Influenza
- Development stage
- Unknown
- Lead developer
- Emory University
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The quadrivalent seasonal influenza vaccine-Emory University-Yellow Fever-Influenza refers to the comparative use of two distinct FDA-approved vaccines—the quadrivalent seasonal influenza vaccine (QIV) and the live-attenuated Yellow Fever 17D vaccine (YF-VAX)—within a Phase 4 systems biology study conducted by Emory University. The study, titled "Systems Biological Assessment of the Durability of Vaccine Responses" (NCT04424238), aims to identify the biological determinants of long-lasting immunity by contrasting the highly durable response of the yellow fever vaccine (which can last decades) with the transient response of the seasonal influenza vaccine. Participants receive either the QIV, which targets two influenza A and two influenza B strains, or the YF-VAX, which utilizes the 17D-204 strain of the yellow fever virus. The research involves longitudinal sampling of blood, lymph nodes, and bone marrow to map the immune landscape and identify signatures of vaccine durability.
- Brand names
- YF-VAX
- Other names
- QIVYF-17DYF17DYF 17DLive Attenuated Yellow Fever 17D VaccineQuadrivalent seasonal influenza vaccine
02
Targets
YFV E (Yellow fever virus envelope protein)HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent seasonal influenza vaccine-Emory University-Yellow Fever-Influenza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent seasonal influenza vaccine-Emory University-Yellow Fever-Influenza.